Patents Examined by Larry D Riggs, II
-
Patent number: 11923049Abstract: A genomic data analyzer system method to analyze next generation sequencing genomic data from a sourcing laboratory. The method includes receiving, with a processor, a next generation sequencing analysis request from a sourcing laboratory, the next generation sequencing request comprising at least a raw next generation sequencing data file and the sourcing laboratory identification; identifying, with a processor, a first set of characteristics associated with the next generation sequencing analysis request, the first set of characteristics comprising at least a target enrichment technology identifier, a sequencing technology identifier, and a genomic context identifier; configuring, with a processor, a data alignment module to align the input raw sequencing data file in accordance with at least one characteristic of said first set of characteristics; and aligning, with the data alignment module processor, the input sequencing data to a genomic sequence.Type: GrantFiled: June 19, 2017Date of Patent: March 5, 2024Assignee: SOPHIA GENETICS S.A.Inventors: Lin Song, Tamara Steijger, Jonas Behr, Adam Novak, David Hernandez, Zhenyu Xu
-
Patent number: 11901043Abstract: Disclosed is a sequence analysis method for analyzing nucleic acid sequence, the sequence analysis method including: obtaining a plurality of read sequences read from the nucleic acid sequence; and determining each nucleic acid sequence by aligning each read sequence with reference to a single reference sequence, wherein the reference sequence includes at least a first rearrangement sequence and a second rearrangement sequence that is different from the first rearrangement sequence.Type: GrantFiled: November 9, 2018Date of Patent: February 13, 2024Assignees: National Cancer Center, Mitsui Knowledge Industry Co., Ltd., Sysmex CorporationInventors: Mamoru Kato, Hideya Kuwabara, Tomohiro Sakuma, Fumio Inoue, Kenichiro Suzuki
-
Patent number: 11848074Abstract: A method for determining an optimized nucleotide sequence encoding a predetermined amino acid sequence, wherein the nucleotide sequence is optimized for expression in a host cell, and wherein the method comprises the steps of: (a) generating a plurality of candidate nucleotide sequences encoding the predetermined amino acid sequence; (b) obtaining a sequence score based on a scoring function based on a plurality of sequence features that influence protein expression in the host cell using a statistical machine learning algorithm, wherein the plurality of sequence features comprises one or more sequence features selected from the group consisting of protein per time, average elongation rate and accuracy for each of the plurality of candidate nucleotide sequences of step (a); and (c) determining the candidate nucleotide sequence with optimized protein expression in the host cell as the optimized nucleotide sequence.Type: GrantFiled: December 6, 2017Date of Patent: December 19, 2023Assignee: GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVERInventors: Reinhard Lipowsky, Sophia Rudorf, Holger Lossner, Jan-Hendrik Trosemeier, Ina Koch, Christel Kamp
-
Patent number: 11842794Abstract: Systems and methods for variant calling in single molecule sequencing from a genomic dataset using a convolutional deep neural network. The method includes: transforming properties of each of the variants into a multi-dimensional tensor; passing the multi-dimensional tensors through a trained convolutional deep neural network to predict categorical output variables, the convolutional deep neural network minimizing a cost function iterated over each variant, the convolutional deep neural network trained using a training genomic dataset including previously identified variants, the convolutional neural network including: a plurality of pooled convolutional layers and at least two fully-connected layers connected sequentially after the last of the pooled convolutional layers, the at least two fully-connected layers comprising a second fully-connected layer connected sequentially after a first fully-connected layer; and outputting the predicted categorical output variables.Type: GrantFiled: March 19, 2019Date of Patent: December 12, 2023Assignee: THE UNIVERSITY OF HONG KONGInventors: Ruibang Luo, Tak-Wah Lam, Chi-Man Liu
-
Patent number: 11817179Abstract: The present disclosure provides a method for enriching for multiple genomic regions using a first bait set that selectively hybridizes to a first set of genomic regions of a nucleic acid sample and a second bait set that selectively hybridizes to a second set of genomic regions of the nucleic acid sample. These bait set panels can selectively enrich for one or more nucleosome-associated regions of a genome, said nucleosome-associated regions comprising genomic regions having one or more genomic base positions with differential nucleosomal occupancy, wherein the differential nucleosomal occupancy is characteristic of a cell or tissue type of origin or disease state.Type: GrantFiled: January 17, 2023Date of Patent: November 14, 2023Assignee: Guardant Health, Inc.Inventors: Darya Chudova, Helmy Eltoukhy, Stefanie Ann Ward Mortimer, Diana Abdueva
-
Patent number: 11817177Abstract: The present disclosure provides a method for enriching for multiple genomic regions using a first bait set that selectively hybridizes to a first set of genomic regions of a nucleic acid sample and a second bait set that selectively hybridizes to a second set of genomic regions of the nucleic acid sample. These bait set panels can selectively enrich for one or more nucleosome-associated regions of a genome, said nucleosome-associated regions comprising genomic regions having one or more genomic base positions with differential nucleosomal occupancy, wherein the differential nucleosomal occupancy is characteristic of a cell or tissue type of origin or disease state.Type: GrantFiled: November 14, 2022Date of Patent: November 14, 2023Assignee: Guardant Health, Inc.Inventors: Darya Chudova, Helmy Eltoukhy, Stefanie Ann Ward Mortimer, Diana Abdueva
-
Patent number: 11804285Abstract: A method of detecting biomarkers using an artificial intelligence (AI) deep learning model for conversion data of nucleotide sequences and mutations of population genomes, the method including: collecting nucleotide sequences and mutations of population genomes; generating conversion data by reflecting mutations of diploid genomes in the collected nucleotide sequences; performing an artificial intelligence (AI) deep learning model with the generated conversion data; generating a fully connected network (FCN) by connecting the results obtained by the machine learning; and extracting biomarkers by the learned model.Type: GrantFiled: November 21, 2018Date of Patent: October 31, 2023Assignee: SYNTEKABIO, INC.Inventors: Jongsun Jung, Jaeyun Yoo, Jaemin Seol
-
Patent number: 11781174Abstract: Method and system for quantifying target nucleic acids using real-time amplification and internal calibration adjustment. The approach employs a single fixed data point in combination with a single adjustment calibrator amplified on the instrument that is to be calibrated for approximating a complete calibration curve.Type: GrantFiled: April 17, 2018Date of Patent: October 10, 2023Assignee: GEN-PROBE INCORPORATEDInventors: Sangeetha Vijaysri Nair, Xianqun Wang, Susan K. Yamagata
-
Patent number: 11655297Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.Type: GrantFiled: November 28, 2018Date of Patent: May 23, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.Inventors: Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
-
Patent number: 11613581Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).Type: GrantFiled: October 16, 2018Date of Patent: March 28, 2023Assignee: Pfizer, Inc.Inventors: Manoj Baburao Charati, Yoon-Chi Han, Madan Katragadda, Nicole Melissa Piché-Nicholas, Lawrence Nathan Tumey
-
Patent number: 11497795Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.Type: GrantFiled: October 18, 2019Date of Patent: November 15, 2022Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Takumi Sakai, Genichi Kusakawa, Yugo Uchida
-
Patent number: 11466062Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.Type: GrantFiled: May 6, 2021Date of Patent: October 11, 2022Assignee: MOLECULAR PARTNERS AGInventors: Patrick Amstutz, Valerie Perrine Calabro, Marcel Walser
-
Patent number: 11402393Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.Type: GrantFiled: September 11, 2017Date of Patent: August 2, 2022Assignee: B.R.A.H.M.S GMBHInventors: Joachim Struck, Christian Nickel, Roland Bingisser, Sven Giersdorf, Oliver Hartmann
-
Patent number: 11304988Abstract: Provided herein are compositions and methods for inhibiting tumor cell transendothelial migration by inhibition of kinesin light chain 1, variant 1 (KLC1C) expression and/or activity, and treatment or prevention of cancer and/or metastasis therewith.Type: GrantFiled: January 24, 2019Date of Patent: April 19, 2022Assignee: Northwestern UniversityInventor: William A. Muller
-
Patent number: 11274135Abstract: The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first K residue and a second K residue, at positions corresponding to position 26, and 34, respectively, of GLP-1(7-37) (SEQ ID NO:1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which y is an integer in the range of 6-13; and the linker comprises Chem. 3a: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates.Type: GrantFiled: May 2, 2013Date of Patent: March 15, 2022Assignee: Novo Nordisk A/SInventors: Jacob Kofoed, Patrick W. Garibay
-
Patent number: 11242367Abstract: Described herein are methods for reducing inflammation by administration of an effective amount of silk-derived proteins (SDP) or a fraction thereof to a subject having an inflammatory condition. The methods include the treatment of inflammatory conditions and wounds, including corneal wounds, comprising the topical administration of an effective amount of SDP material as described herein.Type: GrantFiled: August 12, 2017Date of Patent: February 8, 2022Assignee: Silk Technologies, Ltd.Inventors: Brian D. Lawrence, David W. Infanger
-
Patent number: 11235025Abstract: The present invention relates to an Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and to a pharmaceutical composition containing the same as an active ingredient. The Nkx3.2 fragment of the present invention has a function to activate NF-?B at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.Type: GrantFiled: November 9, 2017Date of Patent: February 1, 2022Assignee: ICM CO., LTD.Inventor: Dae-Won Kim
-
Patent number: 11197906Abstract: The present disclosure relates to, among other things, compositions and methods for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain. One aspect of the present disclosure relates to a composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof.Type: GrantFiled: January 23, 2017Date of Patent: December 14, 2021Assignees: On Target Therapeutics LLC, Trustees of Tufts College, Tufts Medical CenterInventors: Charles Cohen, Krishna Kumar, Alan S. Kopin, Benjamin N. Harwood, Venkata S. Raman, Pedram Hamrah
-
Patent number: 11186625Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.Type: GrantFiled: August 18, 2020Date of Patent: November 30, 2021Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla
-
Patent number: 11174288Abstract: Disclosed are peptides comprising an amphiphilic backbone and a cationic heparin-binding motif peptide. The peptides can be used in methods of antimicrobial treatment.Type: GrantFiled: December 5, 2017Date of Patent: November 16, 2021Assignee: Northeastern UniversityInventors: Run Chang, Keerthana Subramanian, Mian Wang, Thomas J. Webster